Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Opinion in Lipidology|October 12, 2011
Novel developments in omega-3 fatty acid-based strategiesMichael H Davidson, Douglas Kling, Kevin C Maki
Expert Review of Cardiovascular Therapy|August 5, 2014
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemiaMichael H Davidson, Alyssa K Phillips, Douglas Kling, et al.
Vascular Health and Risk Management|October 15, 2013
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II studyElliot Offman, Ted Marenco, Sandy Ferber, et al.
Journal of Clinical Pharmacology|May 9, 2024
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for ObicetrapibAllison Dunn, Marc Ditmarsch, John J P Kastelein, et al.
Kidney360|April 4, 2022
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKDKristen L Nowak, Rahul Kakkar, Matt Devalaraja, et al.
Nature Medicine|August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trialStephen J Nicholls, Marc Ditmarsch, John J Kastelein, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 26, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy VolunteersJohn J P Kastelein, Marc Ditmarsch, Andrew Hsieh, et al.
Journal of Clinical Lipidology|February 18, 2014
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trialJohn J P Kastelein, Kevin C Maki, Andrey Susekov, et al.
European Heart Journal|May 25, 2026
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trialsStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
Clinical Therapeutics|September 4, 2013
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)Kevin C Maki, David G Orloff, Stephen J Nicholls, et al.
Pageof 3